S-1: Alpha Cognition Eyes Nasdaq Uplisting with $17.2 Million Share and Warrant Offering

Alpha Cognition Inc. files for a firm commitment offering of shares and warrants to fund Alzheimer's drug development and Nasdaq uplisting.

Summary

• Alpha Cognition Inc., a biopharmaceutical company, is planning a firm commitment offering of up to 1,334,821 common shares along with warrants to purchase an equal number of common shares.
• The assumed combined offering price is $11.20 per share and accompanying warrant, with the warrants exercisable at $15.12.
• The company is also offering pre-funded warrants to certain purchasers who would exceed ownership limits, with an exercise price of $0.0001 per share.
• The offering aims to raise approximately $13.40 million, or $15.47 million if the underwriters' option is fully exercised, to support the FDA review of ALPHA-1062, commercialization efforts, and further research and development.
• Alpha Cognition has applied to list its common shares on the Nasdaq Capital Market under the symbol ACOG and intends to affect a 1-for-20 reverse stock split prior to the uplisting.
• The company is currently focused on FDA review of its NDA for ALPHA-1062, a treatment for mild-to-moderate Alzheimer's disease, with a PDUFA goal date of July 27th, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While it highlights the potential of ALPHA-1062 and the company's plans for commercialization, it also acknowledges the significant risks and challenges associated with drug development, regulatory approval, and financial stability. The company's ongoing losses and need for additional capital raise concerns, while the potential for Nasdaq uplisting and FDA approval provide some optimism.

Positives

• ALPHA-1062 is a patented product with a potentially reduced side effect profile compared to existing treatments.
• The company has a Prescription Drug User Fee Act (PDUFA) goal date of July 27th, 2024.
• The company has a management team with experience in drug development and commercialization.
• The company has a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the FDA for mild-to-moderate Alzheimers Disease, into 2044.

Negatives

• The company is a pre-commercial stage biopharmaceutical company with no products approved for commercial sale and has incurred significant losses since its inception.
• The company will need substantial additional capital to meet its financial obligations and to pursue its business objectives.
• There is no guarantee that the Company will be successful launching Alpha Seven as a separately funded entity as described above or at all.
• There is no guarantee that Alpha Seven will be successful in advancing the ALPHA-1062 for use in TBI or mTBI.

Risks

• The company's business is heavily dependent on the successful development, regulatory approval, and commercialization of ALPHA-1062.
• The company may encounter substantial delays in preclinical studies and clinical trials.
• The use of therapeutic candidates could be associated with side effects, adverse events, or other properties or safety risks.
• The company faces significant competition in an environment of rapid technological and scientific change.
• The company relies on third-party suppliers to manufacture its product candidates.
• The company is subject to certain supply chain risks inherent in manufacturing its lead product, ALPHA-1062, and future products with respect to Taiwan.
• The company's success depends on its ability to obtain and maintain patent protection for its technology and product candidates.
• The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• The company will need to increase the size of its organization, and it may experience difficulties in managing growth.
• The company's stock price may be volatile, and investors may not be able to resell common shares at or above the price they paid.
• The company is an emerging growth company and a smaller reporting company, and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, its common stock may be less attractive to investors.
• The company may be a passive foreign investment company under United States tax laws.
• Purchasers in this offering will experience immediate and substantial dilution in the book value of their investment.
• The company has broad discretion to determine how to use the funds raised in this offering, and may use them in ways that may not enhance its operating results or the price of its common stock.
• The company does not currently intend to pay dividends on its common stock, and, consequently, investors' ability to achieve a return on their investment will depend on appreciation in the price of its common stock.
• The company has outstanding warrants denominated in both Canadian and U.S. Dollars, which could result in a significant risk of loss at the date of valuing the risk and cause the Company to incur a significant non-cash derivative liability depending on the exchange rate and share price volatility, share price, risk-free interest rate, and remaining life of the Canadian Dollar denominated warrants.

Future Outlook

The company plans to continue its development and commercialization activities for ALPHA-1062 in mild-to-moderate Alzheimers disease, including commercial manufacturing, and pursue the out-licensing of its TBI indication to Alpha Seven.

Management Comments

• The company's executive team comprises pharmaceutical experts with over 27 drug approvals and 33 commercial launches, specifically in the Central Nervous System and the Alzheimers Disease space.
• The executive team has a combined track record of managing drug development programs that have received regulatory approval and been successfully commercialized.

Industry Context

The document highlights the significant unmet need in the Alzheimer's disease and traumatic brain injury markets, with limited effective treatments currently available. The company positions ALPHA-1062 as a next-generation treatment option with a potentially improved side effect profile.

Comparison to Industry Standards

• The document mentions existing treatments for Alzheimer's disease, including donepezil, rivastigmine, galantamine, and memantine, noting their limitations in efficacy and tolerability.
• It also references Biogen's Aduhelm and Eisai's Leqembi as recently approved disease-modifying therapies, but points out the challenges associated with their accessibility and coverage.
• The document compares ALPHA-1062's mechanism of action to existing acetylcholinesterase inhibitors, highlighting its potential for reduced gastrointestinal side effects and differentiated binding to neuronal nicotinic receptors.
• The document mentions companies developing therapeutics for similar indications, including Biogen, Eli Lilly, Corium, Taurz, Vasopharm, Neuren Pharmaceuticals, Abliva, and AB Science.

Related Party Transactions

• The company has entered into a loan agreement with Alpha Seven a related party through a common director and officers, to advance an amount up to $150,000.
• The company has entered into an ongoing consulting services agreement (the Spartan Consulting Agreement) for a three-year term with Spartan Capital Securities, LLC (Spartan).

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the offering and the reverse stock split.
• Employees may be affected by the company's ability to secure funding and continue operations.
• Patients with Alzheimer's disease could benefit from the successful development and commercialization of ALPHA-1062.
• Suppliers and creditors may be impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• Respond to regulatory questions and inquiries from FDA in a satisfactory manner and negotiate the commercial label and approval of the product with FDA, which is anticipated in Q3 2024.
• Continue development activities and commercialization preparations around ALPHA-1062.
• Complete the out-license the TBI asset into Alpha Seven where Alpha Seven plans to raise the additional capital to advance the TBI program.

Key Dates

Keywords

ALPHA-1062, Alzheimer's disease, Offering, Warrants, Pre-funded warrants, FDA, Nasdaq, Biopharmaceutical, ACOG, Clinical trials